用高通量查识别糖原合成酶激酶3alpha/beta作为HBV转录所需的宿主因子
Hironori Nishitsuji1,2, Yui Naito1, Yuuna Murakami1
1Department of Virology, Fujita Health University School of Medicine, Toyoake, Japan.
Hepatology (Baltimore, Md.)
|January 23, 2025
概括
研究人员确定了糖原合成酶激酶3 (GSK3) 抑制剂作为B型肝炎病毒 (HBV) 感染的潜在治疗方法. 这些GSK3抑制剂通过向FOXK2蛋白来抑制HBV复制,为肝病提供了新的治疗途径.
科学领域:
- 肝病学和病毒学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 乙型肝炎病毒 (HBV) 感染会导致严重的肝脏疾病,如肝硬化和肝细胞癌 (HCC).
- 确定调节HBV复制的宿主因素对于开发新的治疗点至关重要.
- 作为HBV入口受体的甲酸共运输聚 (NTCP) 的发现促进了研究HBV感染的基于细胞的试验的开发.
研究的目的:
- 建立基于HBV的强大的记者基因表达系统,用于宿主因子查.
- 识别调节HBV复制和传播的宿主因素和化合物.
- 调查糖原合成酶激酶3 (GSK3) 和其下游点在HBV感染中的作用.
主要方法:
- 开发一种基于HBV的记者基因表达系统,模仿完整的HBV复制周期.
- 对1827个食品和药物管理局批准的化合物的查,以识别抗HBV药物.
- 蛋白质组分析以确定由GSK3alpha/beta酸化的宿主蛋白质,并通过基因淘汰和救援实验调查它们在HBV复制中的作用.
主要成果:
- 鉴定出GSK3α/β抑制剂 (例如,AZD1080,BIO) 是一种强大的抗HBV化合物,抑制HBeAg和HBsAg的产生.
- 发现GSK3alpha/beta可以酸化叉盒K1/2 (FOXK1/2).
- 淘汰FOXK1/2减少了HBV复制,FOXK2在Ser 424上的酸化对GSK3介导的HBV传播至关重要. 观察到FOXK2可以结合HBV DNA.
结论:
- 开发的基于HBV的查系统有效地发现了新的治疗点.
- GSK3抑制剂代表了有前途的抗HBV药物,向FOXK2-介导的复制途径.
- 针对GSK3/FOXK2轴提供了管理HBV感染的潜在策略.
相关概念视频
Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...


